Alternative Investment Funds
United States
12 September 2024
Dechert LLP’s global capital markets team stands out for its work involving business development companies (BDCs). Thomas Friedmann in Boston represents both domestic and foreign issuers as well as investment banks in connection with public and private securities transactions. Philadelphia’s Stephen Leitzell is especially active in the healthcare and tech sectors. Harry Pangas in Washington DC is noted for his work for BDCs, registered closed-end funds, interval funds, and tender offer funds. The three partners lead the group along with New York-based Anna Tomczyk. David Rosenthal in New York has a strong track record advising corporations, investment banks, and venture capital firms operating in the life sciences space.
Legal 500 Editorial commentary
Key clients
- Aquestive Therapeutics
- B&G Foods
- Bain Capital Specialty Finance
- BC Partners
- BioAtla
- Blackstone
- Business Development Company of America
- Diffusion Therapeutics
- EaglePoint Credit Company
- FS Investment Corporation
Work highlights
Represented AB Private Credit Investors LLC in connection with the formation and launch of AB Private Lending Fund, a publicly offered non-traded business development company.
Represented Crown Holdings, Inc. (“Crown”) in connection with an offering by Crown European Holdings S.A. (the “Issuer”), a subsidiary of the Company, of €600 million of senior unsecured notes due 2030.
Represented Apollo Debt Solutions BDC (the "Fund") in its offering of US$400 million additional principal amount of its 6.700% notes due 2031 (the "Notes") in a private placement.
Lawyers
Practice head
Thomas Friedmann; Stephen Leitzell; Anna Tomczyk
Other key lawyers
David Rosenthal